- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05615194
The Impact of a Single Dexmedetomidine Bolus on Intraoperative Sevoflurane Consumption (DEXHALE)
A Randomized Clinical Study to Assess the Impact of a Single Dexmedetomidine Bolus During Induction of General Anesthesia on Intraoperative Sevoflurane Consumption in Elective Laparoscopic Surgery
Study Overview
Status
Intervention / Treatment
Detailed Description
Inhaled gases have been used since the advent of anesthesia due to their analgesic and dissociative properties. However, these are now part of a growing environmental debate which leads us to reconsider their systematic use for general anesthesia. Sevoflurane is a volatile agent easy to monitor using the Minimal Alveolar Concentration (MAC) facilitating its titration for adequate anesthesia depth. Growing biomedical evidence also highlight its anti-inflammatory and antioxidant effects protecting against ischemia-reperfusion injury in cardiac surgery and, potentially, in organ transplant.
The estimated annual contribution of inhalational anesthetic agents represents about 0.01% of global CO2 production. This data can be illustrated as a commercial airliner flying 418 times around the world. Desflurane is gradually abandoned as its greenhouse effect is 25 times more potent than sevoflurane for an equivalent MAC and fresh gas flow. As low-flow inhalational techniques and scavenging technologies become the standard of practice, anesthesiologists still cannot prevent the gas to be released in the atmosphere .
Alternatives such as total intravenous anesthesia (TIVA) avoid direct greenhouse emission, but their indirect carbon footprint remains a major problem. Propofol has a high potential for bioaccumulation. It has high mobility in soil, resists degradation in aquatic environment and concentrates in adipose tissue of aquatic organism. To control its toxicity, destruction should be done by incineration over 1000°C. Unfortunately, studies prove that 32-49% of dispensed propofol is waisted and is mostly disposed unproperly.
For all these reasons, this research aim to find a way to maintain the use of sevoflurane for its clinical benefits while reducing its consumption to limit the environmental consequences.
The use of dexmedetomidine could help us achieve this greener sevoflurane anesthesia. Dexmedetomidine is a potent, highly selective α-2 adrenergic receptor agonist described as a unique sedative with analgesic and sympatholytic properties. Currently approved for sedation, this molecule shows many advantages compared to hypnotic drugs such as propofol. Although still under investigation, dexmedetomidine would possibly have a lower hazard environmental score. The use of dexmedetomidine also shows promising results regarding the reduction of emergence cough and agitation. Decrease in pain and post-operative nausea and vomiting (PONV) are other benefits of dexmedetomidine providing conditions to promote enhanced recovery after surgery (ERAS).
Many investigations have studied impacts of dexmedetomidine as an adjuvant to general anesthesia for its opioid sparing capacity, and hemodynamics response during laparoscopic surgeries. Fewer research specifically wondered about sevoflurane dispense outcome. Moreover, they don't reflect the anesthesia practice of North America and their sample sizes are low.
This new randomized controlled trial (RCT) will answer the question whether a single bolus of dexmedetomidine (0.6 mcg.kg-1 on 10 minutes during induction) compared to placebo has a clinically significant impact on sevoflurane consumption during laparoscopic elective surgery. Opioid requirement, need for vasopressors, post-operative events (PONV, shivering, critical respiratory event) and time for readiness for Post-Anesthesia Care Unit (PACU) will also be assessed.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H1T2M4
- Recruiting
- Hôpital Maisonneuve-Rosemont, CIUSSS de l'Est de l'Ile de Montréal
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ASA 1-3 patients
- Undergoing laparoscopic surgery of duration time expected under 120 minutes using general anesthesia with sevoflurane
- Fully consented
- Age > 18yo
- No allergy to one of the medications used in this study.
Exclusion Criteria:
- History of severe coronary artery disease; ventricular dysfunction, serious cardiac arrhythmia (including atrial fibrillation and high-grade atrioventricular block)
- Moderate to severe renal or hepatic dysfunction
- Allergy to any drug used in the study protocol
- Refusal of the patient for participation in the study
- History of severe PONV
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Normal saline in volume equivalent of dexmedetomidine dose according to patient weight ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) so that the full dose is delivered over 10 minutes during induction of general anesthesia
|
Volume equivalent in infusion over 10 minutes
Other Names:
|
Active Comparator: Dexmedetomidine
Dexmedetomidine 0.6 mcg/kg (adjusted body weight) ; Administered via infusion pump (Smith Medical Medfusion® 4000 Syringe Infusion Pump) so that the full dose is delivered over 10 minutes during induction of general anesthesia
|
0.6 mcg/kg in infusion over 10 minutes
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sevoflurane consumption expressed in mL.kg-1.h-1
Time Frame: From intubation to end of surgery
|
To compare the total sevoflurane consumption when using a dexmedetomidine single bolus (group D) of 0.6 mcg.kg-1 on 10 minutes during induction versus placebo (group C).
This will be expressed in mL.kg-1.h-1 of surgery.
|
From intubation to end of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total intra-operative remifentanil consumption (in mcg.kg-1)
Time Frame: From intubation to end of surgery
|
To compare the total intra-operative remifentanil consumption during anesthesia based on the NoL index (Medasense Ltd., Ramat Gan, Israel)
|
From intubation to end of surgery
|
Percentage of time during the intraoperative period for which the NOL index will be above the pain threshold of 25 (in % of surgical time)
Time Frame: From intubation to end of surgery
|
To compare the percentage of time during the intraoperative period for which the NOL index will be above the pain threshold of 25
|
From intubation to end of surgery
|
Total amount of hydromorphone given IV in PACU (in mg)
Time Frame: From PACU admission to discharge
|
To quantify the total amount of hydromorphone needed in PACU
|
From PACU admission to discharge
|
Intra-operative and postanesthesia care unit (PACU) doses of vasopressors
Time Frame: From intubation to PACU discharge
|
To compare the intra- and post-operative requirements of phenylephrine, ephedrine, glycopyrrolate and atropine
|
From intubation to PACU discharge
|
Mean end tidal sevoflurane (in %) and MAC needed to maintain the BIS index (Medtronic, Canada) between 40 and 60
Time Frame: From intubation to end of surgery
|
To compare the mean end tidal sevoflurane (EtSevo) and MAC needed to maintain the BIS index between 40 and 60
|
From intubation to end of surgery
|
Total intraoperative time from intubation until end of surgery with BIS index between 40 and 60 (in minutes)
Time Frame: From intubation to end of surgery
|
To compare the % of total intraoperative time from intubation until end of surgery with BIS index between 40 and 60
|
From intubation to end of surgery
|
Time for extubation (in minutes)
Time Frame: From sevoflurane discontinuation to extubation
|
To compare the time for extubation
|
From sevoflurane discontinuation to extubation
|
Time for awakening (in minutes)
Time Frame: From sevoflurane discontinuation to when the patient is opening his eyes
|
To compare the time for awakening
|
From sevoflurane discontinuation to when the patient is opening his eyes
|
Postoperative outcomes such as postoperative nausea and vomiting (PONV), shivering and critical respiratory event (CRE)
Time Frame: From PACU admission to discharge
|
To assess postoperative outcomes such as postoperative nausea and vomiting (PONV), shivering and critical respiratory event (CRE) A CRE will be defined as the occurrence of one of the following criteria:
|
From PACU admission to discharge
|
Total time spent in PACU (in minutes)
Time Frame: From PACU admission to discharge
|
To compare total time for readiness for discharge from PACU between groups assessed by recovery scores (Aldrete's modified score and Maisonneuve-Rosemont PACU score)
|
From PACU admission to discharge
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Respiration Disorders
- Respiratory Aspiration
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- 2023-3190
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sevoflurane
-
Inonu UniversityCompleted
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityRecruiting
-
Eye & ENT Hospital of Fudan UniversityEnrolling by invitation
-
Hospital General Universitario Gregorio MarañonCompleted
-
Dr. Lutfi Kirdar Kartal Training and Research HospitalActive, not recruitingInflammatory Response | Sevoflurane | PropofolTurkey
-
Tao ZhangUnknownSevoflurane | Cesarean Section | PropofolChina
-
Sakarya UniversityCompletedSevoflurane | Anesthesia | MonitoringTurkey
-
Shanghai Ninth People's Hospital Affiliated to...UnknownEndotracheal Intubation | SevofluraneChina
-
Maharashtra University of Health SciencesJaslok Hospital and Research CentreCompletedMuscle Relaxation Caused by SevofluraneIndia
-
Mansoura UniversityCompletedElective Laparoscopic Cholecystectomy | Sevoflurane AnesthesiaEgypt
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States